Efficacy of artesunate-amodiaquine and artemether-lumefantrine fixed-dose combinations for the treatment of uncomplicated Plasmodium falciparum malaria among children aged six to 59 months in Nimba County, Liberia: an open-label randomized non-inferiority trial.

Hdl Handle:
http://hdl.handle.net/10144/302750
Title:
Efficacy of artesunate-amodiaquine and artemether-lumefantrine fixed-dose combinations for the treatment of uncomplicated Plasmodium falciparum malaria among children aged six to 59 months in Nimba County, Liberia: an open-label randomized non-inferiority trial.
Authors:
Schramm, Birgit; Valeh, Parastou; Baudin, Elisabeth; Mazinda, Charles S; Smith, Richard; Dhorda, Mehul; Boum, Yap II; Sundaygar, Timothy; Zolia, Yah M; Jones, Joel J; Comte, Eric; Houzé, Pascal; Jullien, Vincent; Carn, Gwenaelle; Kiechel, Jean-René; Ashley, Elizabeth A; Guérin, Philippe J
Journal:
Malaria Journal
Abstract:
Prospective efficacy monitoring of anti-malarial treatments is imperative for timely detection of resistance development. The in vivo efficacy of artesunate-amodiaquine (ASAQ) fixed-dose combination (FDC) was compared to that of artemether-lumefantrine (AL) among children aged six to 59 months in Nimba County, Liberia, where Plasmodium falciparum malaria is endemic and efficacy data are scarce.
Affiliation:
Epicentre, 75011 Paris, France. birgit.schramm@epicentre.msf.org
Publisher:
BioMed Central Ltd.
Issue Date:
17-Jul-2013
URI:
http://hdl.handle.net/10144/302750
DOI:
10.1186/1475-2875-12-251
PubMed ID:
23866774
Language:
en
ISSN:
1475-2875
Appears in Collections:
Malaria

Full metadata record

DC FieldValue Language
dc.contributor.authorSchramm, Birgiten_GB
dc.contributor.authorValeh, Parastouen_GB
dc.contributor.authorBaudin, Elisabethen_GB
dc.contributor.authorMazinda, Charles Sen_GB
dc.contributor.authorSmith, Richarden_GB
dc.contributor.authorDhorda, Mehulen_GB
dc.contributor.authorBoum, Yap IIen_GB
dc.contributor.authorSundaygar, Timothyen_GB
dc.contributor.authorZolia, Yah Men_GB
dc.contributor.authorJones, Joel Jen_GB
dc.contributor.authorComte, Ericen_GB
dc.contributor.authorHouzé, Pascalen_GB
dc.contributor.authorJullien, Vincenten_GB
dc.contributor.authorCarn, Gwenaelleen_GB
dc.contributor.authorKiechel, Jean-Renéen_GB
dc.contributor.authorAshley, Elizabeth Aen_GB
dc.contributor.authorGuérin, Philippe Jen_GB
dc.date.accessioned2013-10-04T19:23:30Z-
dc.date.available2013-10-04T19:23:30Z-
dc.date.issued2013-07-17-
dc.identifier.citationEfficacy of artesunate-amodiaquine and artemether-lumefantrine fixed-dose combinations for the treatment of uncomplicated Plasmodium falciparum malaria among children aged six to 59 months in Nimba County, Liberia: an open-label randomized non-inferiority trial. 2013, 12:251 Malar. J.en_GB
dc.identifier.issn1475-2875-
dc.identifier.pmid23866774-
dc.identifier.doi10.1186/1475-2875-12-251-
dc.identifier.urihttp://hdl.handle.net/10144/302750-
dc.description.abstractProspective efficacy monitoring of anti-malarial treatments is imperative for timely detection of resistance development. The in vivo efficacy of artesunate-amodiaquine (ASAQ) fixed-dose combination (FDC) was compared to that of artemether-lumefantrine (AL) among children aged six to 59 months in Nimba County, Liberia, where Plasmodium falciparum malaria is endemic and efficacy data are scarce.en_GB
dc.language.isoenen
dc.publisherBioMed Central Ltd.en_GB
dc.rightsPublished by BioMed Central, [url]http://www.malariajournal.com/[/url] Archived on this site by Open Access permissionen_GB
dc.subjectMalariaen_GB
dc.subjectPediatricsen_GB
dc.titleEfficacy of artesunate-amodiaquine and artemether-lumefantrine fixed-dose combinations for the treatment of uncomplicated Plasmodium falciparum malaria among children aged six to 59 months in Nimba County, Liberia: an open-label randomized non-inferiority trial.en
dc.contributor.departmentEpicentre, 75011 Paris, France. birgit.schramm@epicentre.msf.orgen_GB
dc.identifier.journalMalaria Journalen_GB

Related articles on PubMed

All Items in MSF are protected by copyright, with all rights reserved, unless otherwise indicated.